<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-17-03-2026-shutterstock_2556717557-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-17-03-2026-shutterstock_2556717557-430x241.jpg"/></p>
<p>该项目正在完成 IIA 期临床试验，预计在 2026 年上半年结束前公布数据。图片来源：Gorodenkoff / Shutterstock.com。</p>
<p>Zydus Lifesciences 的子公司 Sentynl Therapeutics 已与韩国公司 PRG S&amp;T 签署协议，获得 Progerinin（SLC-D011）的许可，这是一种用于治疗哈钦森 - 吉尔福德早衰综合症（HGPS）的研究分子。</p>
<p>此举使 Sentynl 能够立即与 PRG S&amp;T 合作，推进该分子的临床开发，该分子已获得美国食品药品监督管理局（FDA）的孤儿药资格。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - Donaperminogene Seltoplasmid 在肌萎缩侧索硬化症中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - PR-006 在额颞叶痴呆（FTD）中的应用</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>Sentynl 将获得 Progerinin 的全部权利，前提是达到某些里程碑。该项目目前正在完成 IIA 期临床试验，预计在 2026 年上半年结束前公布数据。</p>
<p>一旦完成，该疗法将成为 Sentynl 针对 HGPS 的第二个产品。</p>
<p>Progerinin 是一种口服活性小分子药物，正在开发用于治疗 HGPS，这是一种由 LMNA 基因突变引起的罕见疾病，导致 progerin 积累和细胞过早老化。</p>
<p>该药物旨在抑制 progerin 在细胞内的影响，可能改善细胞核的完整性并减少损伤。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报</p>
<p>Progerinin 目前尚未获得任何卫生机构的批准。早期研究和临床试验旨在评估其是否能够减缓 HGPS 患者的疾病进展并改善生存率。</p>
<p>Zydus Lifesciences 的董事总经理 Dr Sharvil Patel 表示：“此次收购标志着我们在扩大哈钦森 - 吉尔福德早衰综合症治疗组合方面的重要一步，如果不加以治疗，该病可能对患者健康产生严重影响。</p>
<p>“支持患者过上健康、充实的生活是我们工作的核心，与 PRG S&amp;T 的协议直接推动了这一使命，通过推进孤儿药物治疗影响罕见疾病的患者和家庭。”</p>
<p>Sentynl 首席执行官 Matt Heck 表示：“患有哈钦森 - 吉尔福德早衰综合症的儿童面临着无情的疾病。然而，我们在早衰研究中看到了真正的进展，新科学正在改变可能性。</p>
<p>“这项协议将 Progerinin 纳入我们的早衰产品组合，代表了我们将这一进展转化为另一个真正疗法的承诺，以帮助需要它的儿童和家庭。”</p>
<p>在 2024 年 5 月，Sentynl 宣布全球收购 Eiger BioPharmaceuticals 的 Zokinvy（lonafarnib）项目，用于治疗早衰。</p>

医药突破 ETF - ALPS

ZYXIQ

生物科技 ETF - VanEck Vectors

<p>Sentynl Therapeutics 已与 PRG S&T 达成合作，获得了用于治疗哈钦森 - 吉尔福德早衰综合症（HGPS）的实验性药物 Progerinin 的许可。该药物目前正在进行 IIA 期临床试验，预计将在 2026 年中期公布结果。Sentynl 将在达到特定里程碑后获得 Progerinin 的完全权利。这项协议增强了 Sentynl 针对罕见疾病的产品组合，体现了他们改善 HGPS 患者生活的承诺</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-17-03-2026-shutterstock_2556717557-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-17-03-2026-shutterstock_2556717557-430x241.jpg"/></p>
<p>The programme is completing a Phase IIA trial, with data expected before the end of H1 2026. Credit: Gorodenkoff / Shutterstock.com.</p>
<div class="lb-trans"><p>该项目正在完成 IIA 期临床试验，预计在 2026 年上半年结束前公布数据。图片来源：Gorodenkoff / Shutterstock.com。</p>
</div><p>Zydus Lifesciences subsidiary Sentynl Therapeutics has signed an agreement with Korean company PRG S&amp;T to license Progerinin (SLC-D011), an investigational molecule intended to treat Hutchinson-Gilford Progeria Syndrome (HGPS).</p>
<div class="lb-trans"><p>Zydus Lifesciences 的子公司 Sentynl Therapeutics 已与韩国公司 PRG S&amp;T 签署协议，获得 Progerinin（SLC-D011）的许可，这是一种用于治疗哈钦森 - 吉尔福德早衰综合症（HGPS）的研究分子。</p>
</div><p>The move enables Sentynl to collaborate immediately with PRG S&amp;T to advance clinical development of the molecule, which holds orphan drug status from the US Food and Drug Administration (FDA).</p>
<div class="lb-trans"><p>此举使 Sentynl 能够立即与 PRG S&amp;T 合作，推进该分子的临床开发，该分子已获得美国食品药品监督管理局（FDA）的孤儿药资格。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Donaperminogene Seltoplasmid in Amyotrophic La...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Donaperminogene Seltoplasmid 在肌萎缩侧索硬化症中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - PR-006 in Frontotemporal Dementia (FTD)</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - PR-006 在额颞叶痴呆（FTD）中的应用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Sentynl will acquire full rights to Progerinin, provided certain milestones are achieved. The programme is presently completing a Phase IIA clinical trial, with data anticipated before the end of the first half of 2026.</p>
<div class="lb-trans"><p>Sentynl 将获得 Progerinin 的全部权利，前提是达到某些里程碑。该项目目前正在完成 IIA 期临床试验，预计在 2026 年上半年结束前公布数据。</p>
</div><p>Upon closing, this therapy would become Sentynl’s second offering aimed at treating HGPS.</p>
<div class="lb-trans"><p>一旦完成，该疗法将成为 Sentynl 针对 HGPS 的第二个产品。</p>
</div><p>Progerinin is an orally active small-molecule drug, which is being developed as a treatment for HGPS, a rare condition caused by mutations in the LMNA gene resulting in progerin accumulation and premature cellular ageing.</p>
<div class="lb-trans"><p>Progerinin 是一种口服活性小分子药物，正在开发用于治疗 HGPS，这是一种由 LMNA 基因突变引起的罕见疾病，导致 progerin 积累和细胞过早老化。</p>
</div><p>The drug aims to inhibit progerin’s effects within cells, potentially improving nuclear integrity and reducing damage.</p>
<div class="lb-trans"><p>该药物旨在抑制 progerin 在细胞内的影响，可能改善细胞核的完整性并减少损伤。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>Progerinin is not currently approved by any health authority. Early research and clinical studies are designed to assess whether it can slow disease progression and improve survival in HGPS patients.</p>
<div class="lb-trans"><p>Progerinin 目前尚未获得任何卫生机构的批准。早期研究和临床试验旨在评估其是否能够减缓 HGPS 患者的疾病进展并改善生存率。</p>
</div><p>Zydus Lifesciences managing director Dr Sharvil Patel said: “This acquisition marks an important step in growing our portfolio of therapies for Hutchinson-Gilford Progeria Syndrome, which can have severe impacts on patient health if left untreated.</p>
<div class="lb-trans"><p>Zydus Lifesciences 的董事总经理 Dr Sharvil Patel 表示：“此次收购标志着我们在扩大哈钦森 - 吉尔福德早衰综合症治疗组合方面的重要一步，如果不加以治疗，该病可能对患者健康产生严重影响。</p>
</div><p>“Supporting patients in living healthy, fulfilled lives is core to what we do, and the agreement with PRG S&amp;T directly furthers this mission by advancing orphan therapies for patients and families impacted by rare diseases.”</p>
<div class="lb-trans"><p>“支持患者过上健康、充实的生活是我们工作的核心，与 PRG S&amp;T 的协议直接推动了这一使命，通过推进孤儿药物治疗影响罕见疾病的患者和家庭。”</p>
</div><p>Sentynl CEO Matt Heck said: “Children with Hutchinson-Gilford Progeria Syndrome face an unforgiving disease. However, we are seeing real progress in progeria research, with new science changing what’s possible.</p>
<div class="lb-trans"><p>Sentynl 首席执行官 Matt Heck 表示：“患有哈钦森 - 吉尔福德早衰综合症的儿童面临着无情的疾病。然而，我们在早衰研究中看到了真正的进展，新科学正在改变可能性。</p>
</div><p>“This agreement, which will add Progerinin to our progeria portfolio, represents our commitment to translating that progress into another real therapy for children and families who need them.”</p>
<div class="lb-trans"><p>“这项协议将 Progerinin 纳入我们的早衰产品组合，代表了我们将这一进展转化为另一个真正疗法的承诺，以帮助需要它的儿童和家庭。”</p>
</div><p>In May 2024, Sentynl announced the worldwide acquisition of the Zokinvy (lonafarnib) programme from Eiger BioPharmaceuticals for the treatment of progeria.</p>
<div class="lb-trans"><p>在 2024 年 5 月，Sentynl 宣布全球收购 Eiger BioPharmaceuticals 的 Zokinvy（lonafarnib）项目，用于治疗早衰。</p>
</div>

Sentynl 与 PRG 合作获得 Progerinin 的许可